TNFAIP6 and brain injury: This is far lower than the dose of recombinant TSG-6 that promoted beneficial effects in this model of traumatic brain injury (50 μg/mouse, intravenous) [55], suggesting that there may be other molecules in BM-MSC-derived extracellular vesicles that act synergistically with TSG-6 or that there are differences in the bioavailability of TSG-6 in these two conditions.